Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies

Benza, Raymond L.; Park, Myung H.; Keogh, Anne; Girgis, Reda E.

doi:10.1016/j.healun.2007.01.035

Cited by 67 publications

(51 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,4,5 In the Bologna PAH experience, age and sex were important risk factors in some clinical subgroups but not all, whereas cardiac output was not identified as a risk factor, in contrast with the French registry. 30 In this study, we found that a CI >3.0 L/min per m 2 was associated with a good outcome.…”

Section: Risk Factors Of Survivalsupporting

confidence: 47%

See 1 more Smart Citation

Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension

Grapsa

Nunes

Tan

et al. 2015

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

Consecutive patients with precapillary PH referred to the National Pulmonary Hypertension Service at Hammersmith Hospital between Background-In this study, we looked at the prognostic value of echocardiographic and hemodynamic measures in a large cohort of patients with precapillary pulmonary hypertension before and after initiation of treatment. were independent predictors of mortality. High pulmonary vascular resistance and right atrial pressure by invasive hemodynamic measurements were independent predictors of mortality (HR, 1.084; 95% confidence interval, 1.041-1.130, and 1.079, respectively; 95% confidence interval, 1.049-1.111; P<0.001 for both), whereas patients with a higher cardiac index had better survival overall (HR, 0.384; 95% confidence interval, 0.307-0.481; P<0.001). Conclusions-Right ventricular dysfunction, moderate-severe tricuspid regurgitation, low cardiac index, and raised right atrial pressure were associated with poor survival for both pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensive disease patients. The severity of tricuspid regurgitation, myocardial performance index, presence of pericardial effusion, pulmonary vascular resistance, cardiac index, and right atrial pressure may be used to stratify risk of death. (Circ Cardiovasc Imaging. 2015;8:e002107.

show abstract

Section: Risk Factors Of Survivalsupporting

confidence: 47%

“…30,31 Female sex was a poor prognostic marker for PAH but not for patients with CTEPH. In the French registry, the female/male ratio is 1.7, but this increases to 4 in the Registry to Evaluate Early and LongTerm Pulmonary Arterial Hypertension Disease Management (REVEAL).…”

Section: Assessment Of Confounding Factorsmentioning

confidence: 90%

Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension

Grapsa

Nunes

Tan

et al. 2015

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

show abstract

“…Overall, it appears that the presence of RLS was associated with certain measures of better prognosis previously described in the PH literature. 16 -18 This was not explained by differences in the use of vasoactive medications for PH 19 (including prostanoid analogs) or prostanoid titration strategy. The validity and significance of this finding, if any, requires further study.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Characteristics of Restless Legs Syndrome in Patients With Pulmonary Hypertension

Minai

Malik

Foldvary

et al. 2008

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Therefore, the use of combination therapy is increasingly being applied in the treatment of PAH patients. Recent studies indicate that a combination of bosentan and sildenafil can be beneficial [31,32]. In a recent study, a combination of fasudil and beraprost was more beneficial than the respective single treatments [29], but the combination of fasudil with the more commonly used PAH medications, such as bosentan and sildenafil, has not been examined.…”

Section: Discussionmentioning

confidence: 99%

Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil

Mouchaers¹,

Schalij²,

Boer³

et al. 2010

Eur Respir J

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) still cannot be cured, warranting the search for novel treatments.Fasudil (a Rho kinase inhibitor) was compared with bosentan (an endothelin receptor blocker) and sildenafil (a phosphodiesterase 5 inhibitor), with emphasis on right ventricular (RV) function, in a reversal rat model of monocrotaline (MCT)-induced PAH. In addition, the effects of combining bosentan or sildenafil with fasudil were studied.MCT (40 mg?kg body weight -1) induced clear PAH in male Wistar rats (n59). After 28 days, echocardiography, RV catheterisation and histochemistry showed that cardiac frequency, stroke volume and RV contractility had deteriorated, accompanied by RV dilatation and hypertrophy, and marked pulmonary arterial wall thickening. Mean pulmonary arterial pressure and pulmonary vascular resistance increased significantly compared to healthy rats (n59). After 14 days, MCTtreated rats received a 14-day oral treatment with bosentan, sildenafil, fasudil or a combination of fasudil with either bosentan or sildenafil (all n59). All treatments preserved cardiac frequency, stroke volume and RV contractility, and reduced pulmonary vascular resistance and RV dilatation. Fasudil lowered RV systolic pressure and mean pulmonary arterial pressure significantly, by reducing pulmonary arterial remodelling, which reduced RV hypertrophy. Combining bosentan or sildenafil with fasudil had no synergistic effect.Fasudil significantly improved PAH, to a greater degree than did bosentan and sildenafil.

show abstract

Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies

Cited by 67 publications

References 49 publications

Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension

Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension

Prevalence and Characteristics of Restless Legs Syndrome in Patients With Pulmonary Hypertension

Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil

Contact Info

Product

Resources

About